Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial.

Wortelboer N, Kent S, Konings IR, van Ommen-Nijhof A, van der Noort V, van den Pol E, Guerrero Páez C, van Bekkum ML, van den Berkmortel FWPJ, Droogendijk HJ, Houtsma D, Oosterkamp HM, van der Padt-Pruijsten A, Siemerink EJM, Tol J, van Zweeden AA, van Leeuwen-Stok AE, Sonke GS, Jager A, Blommestein HM

Open source

DOI: 10.1016/j.ejca.2025.116051
Published: 2025 Dec 9
Container: European journal of cancer (Oxford, England : 1990)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ejca.2025.116051,
  title = {Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial.},
  author = {Wortelboer N and Kent S and Konings IR and van Ommen-Nijhof A and van der Noort V and van den Pol E and Guerrero Páez C and van Bekkum ML and van den Berkmortel FWPJ and Droogendijk HJ and Houtsma D and Oosterkamp HM and van der Padt-Pruijsten A and Siemerink EJM and Tol J and van Zweeden AA and van Leeuwen-Stok AE and Sonke GS and Jager A and Blommestein HM},
  year = {2025},
  journal = {European journal of cancer (Oxford, England : 1990)},
  doi = {10.1016/j.ejca.2025.116051},
  url = {https://doi.org/10.1016/j.ejca.2025.116051}
}

RIS

TY  - JOUR
TI  - Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial.
AU  - Wortelboer N
AU  - Kent S
AU  - Konings IR
AU  - van Ommen-Nijhof A
AU  - van der Noort V
AU  - van den Pol E
AU  - Guerrero Páez C
AU  - van Bekkum ML
AU  - van den Berkmortel FWPJ
AU  - Droogendijk HJ
AU  - Houtsma D
AU  - Oosterkamp HM
AU  - van der Padt-Pruijsten A
AU  - Siemerink EJM
AU  - Tol J
AU  - van Zweeden AA
AU  - van Leeuwen-Stok AE
AU  - Sonke GS
AU  - Jager A
AU  - Blommestein HM
PY  - 2025
JO  - European journal of cancer (Oxford, England : 1990)
DO  - 10.1016/j.ejca.2025.116051
UR  - https://doi.org/10.1016/j.ejca.2025.116051
ER  -

APA

N, W., S, K., IR, K., A, V. O., V, V. D. N., E, V. D. P., C, G. P., ML, V. B., FWPJ, V. D. B., HJ, D., D, H., HM, O., A, V. D. P., EJM, S., J, T., AA, V. Z., AE, V. L., GS, S., A, J., & HM, B. (2025). Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial.. European journal of cancer (Oxford, England : 1990). https://doi.org/10.1016/j.ejca.2025.116051

Source records

pubmed · retrieved 2026-09-27T12:06:10.299Z